Bristol Myers Squibb (CELG-RI) Acquisitions (2009 - 2026)
Bristol Myers Squibb (CELG-RI) posted quarterly Acquisitions of $91.0 million for Q2 2026, down 68.07% year-over-year from $285.0 million in Q2 2025, and up 40.0% quarter-over-quarter from $65.0 million in Q1 2026.
Bristol Myers Squibb (CELG-RI) Acquisitions (2009 - 2026) Analysis & Trends
Bristol Myers Squibb (CELG-RI) has reported Acquisitions for 16 consecutive years, with $91.0 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Acquisitions fell 68.07% year-over-year to $91.0 million; the TTM figure through Jun 2026 stood at $3.7 billion (up 393.01% YoY), while the FY2025 annual figure was $3.9 billion, down 81.93% from the prior year.
- Acquisitions grew to $91.0 million in Q2 2026 per CELG-RI's latest filing, from $65.0 million in the prior quarter.
- Across five years, Acquisitions topped out at $20.1 billion in Q1 2024 and bottomed at $47.0 million in Q4 2024.
- Historically, Acquisitions has averaged $1.7 billion across 5 years, with a median of $337.0 million in 2023.
- Annual changes were most pronounced in 2024 — Acquisitions jumped 25608.97% — and 2025, when it slumped 99.61%.
- Bristol Myers Squibb's Acquisitions stood at $116.0 million in 2022, then surged by 400.86% to $581.0 million in 2023, then sank by 91.91% to $47.0 million in 2024, then surged by 3531.91% to $1.7 billion in 2025, then slumped by 94.67% to $91.0 million in 2026.
- Business Quant data shows CELG-RI's Acquisitions at $91.0 million in Q2 2026, $65.0 million in Q1 2026, and $1.7 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Acquisitions (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | -17.24 Bn |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | - |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | - |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | - |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | 11.21 Bn |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | - |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | - |
| 10 | Bristol Myers Squibb | 188.27 Mn | -10.88 Bn | 9.25 Bn | 91.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 91.00 Mn |
| Mar 31, 2026 | 65.00 Mn |
| Dec 31, 2025 | 1.71 Bn |
| Sep 30, 2025 | 1.87 Bn |
| Jun 30, 2025 | 285.00 Mn |
| Mar 31, 2025 | 78.00 Mn |
| Dec 31, 2024 | 47.00 Mn |
| Sep 30, 2024 | 348.00 Mn |
| Jun 30, 2024 | 1.37 Bn |
| Mar 31, 2024 | 20.05 Bn |
| Dec 31, 2023 | 581.00 Mn |
| Sep 30, 2023 | 326.00 Mn |
| Jun 30, 2023 | 184.00 Mn |
| Mar 31, 2023 | 78.00 Mn |
| Dec 31, 2022 | 116.00 Mn |
| Sep 30, 2022 | 3.26 Bn |
| Jun 30, 2022 | 467.00 Mn |
| Mar 31, 2022 | 442.00 Mn |
| Dec 31, 2021 | 152.00 Mn |
| Sep 30, 2021 | 1.06 Bn |